Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Delhi HC given Green...

    Delhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug Ceritinib

    Farhat NasimWritten by Farhat Nasim Published On 2019-09-01T14:33:55+05:30  |  Updated On 16 Aug 2021 12:13 PM IST

    New Delhi: In a major relief to Natco, the Delhi High Court has lifted a ban on Natco Pharma from manufacturing fresh stock of on-small cell lung cancer (NSCLC) drug API Ceritinib. The court has suspended the previous ruling which barred Natco Pharma from manufacturing drugs consisting of active pharmaceutical ingredient (API) 'Ceritinib'.


    Justice Prathiba M. Singh in an order dated August 20, 2019, set aside the restrictions imposed on Natco Pharma from manufacturing and selling Ceritinib which had come in wake of a petition filed by Swiss pharma major Novartis AG.


    Novartis, in its injunction application, had claimed to have been granted a patent for Ceritinib which it said was a "novel and inventive compound" for treatment of non-small cell lung cancer (NSCLC). The firm submitted that the suit patent was filed as a Patent Convention Treaty application claiming priority since 2007, and was granted on 28th September 2015.






    On March 29, the company had come across 'Ceritinib capsules' launched by Natco Pharma under the mark Noxalk at a pharmaceutical conference at Kolkata. Following this, Novartis moved the court.




    On the other hand, Natco pharma had contended that the molecule Ceritinib is neither novel nor inventive and is covered under the broad Markush formula which is disclosed in the AstraZeneca and Rigel patents, and two earlier Novartis patents.


    Hearing the contention, the court had earlier stayed the manufacturing of the product;


    "Natco Pharma, having been well aware of the fact that the patent stood granted and the fact that the post-grant opposition was pending adjudication, ought not to have launched the product while the decision was pending in the Patent Office. Accordingly, the Defendant is restrained from carrying out any fresh manufacturing of pharmaceutical preparations comprising of the active pharmaceutical ingredient (API) 'Ceritinib' till the next date,"

    However, the ruling permitted Natco to continue selling products that had already been manufactured. The matter was adjourned for July 11.


    Also Read: Setback: Delhi HC restricts Natco Pharma from manufacturing cancer drug Ceritinib


    On July 11 2019, the matter was again brought up before the court. The court directed that the Controller General shall go ahead and proceed to pass orders in the post-grant opposition within a period of one month from today.


    Earlier this month, the controller ruled that Novartis' patent "lacked novelty", and removed protection for Ceritinib.


    in the latest hearing, Natco Pharma informed the court that the order in the post-grant opposition proceeding has since been passed on 16th August 2019 and the patent has been revoked. The court then observed




    A perusal of the said order passed by the Controller shows that, after examining the matter, it has been held that the suit patent lacks Novelty and the patent has thereafter been revoked. Once a patent is revoked, a suit for infringement of the patent itself would not be maintainable.



    However, Mr Hemant Singh, Novartis counsel, submitted that the order passed in the post-grant opposition proceedings has been appealed against by Novartis and the same was listed before the Intellectual Property Appellate Board (IPAB) on 19th August 2019.


    The court said Novartis was "at liberty" to seek a further order should IPAB rule in its favour.




    The Plaintiffs are, however, granted liberty to seek appropriate orders if any orders are passed in favour of the Plaintiffs by the IPAB, in the appeal preferred by them. Accordingly, I.A under Order XXXIX Rule 4 CPC is disposed of. I. A under Order VII Rule 11 CPC be listed on the next date.



    The Delhi High Court has now put that order into effect, lifting the ban on Natco manufacturing generics of the drug Ceritinib.







    AstraZenecacancerceritinibCertinibDelhiDelhi high courtdrug patentJustice Pratibha M SinghKolkatalung cancerNatcoNatco pharmaNovartisNovartis AGNOXALKNSCLCpatentPatent Convention Treatypatent disputePatents Actpharmaceutical conferenceRigel patentRight To Access Medicine

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok